Equity · Healthcare
GMAB
NASDAQGenmab A/s (GMAB)
The line runs 45.20 USD on 26 October through 50.62 USD on 20 November, on a scale from 40 to 60. Days the market did not trade hold the previous close, flat.
- Revenue, year to Dec 2025
- 3.7B USD
- EPS, diluted, year to Dec 2025
- 15.37 USD
- 52-week range
- 23.85 USD – 57.34 USD
- Avg volume
- 590.9K
- Mentions, 30 days
- 1
as of Nov 20, 2026
Which funds hold Genmab A/s (GMAB)?
8 of the 45 institutional funds we track reported a Genmab A/s position for the quarter ended 30 Sep 2026 — a combined 531.9M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Two Sigma Investments | Added | 5,252,719 | 187.4M USD | +49.8% |
| Point72 Asset Management | Added | 3,535,080 | 126.1M USD | +2,506.1% |
| Renaissance Technologies | Trimmed | 2,272,450 | 81.1M USD | −35.4% |
| Citadel Advisors | Trimmed | 1,729,323 | 61.7M USD | −30.2% |
| Marshall Wace | Added | 1,219,998 | 43.5M USD | +47.0% |
| Millennium Management | Held (±25%) | 756,496 | 27.0M USD | −16.9% |
| AQR Capital Management | Added | 133,582 | 4.8M USD | +25.9% |
| Maverick Capital | New position | 10,683 | 381K USD |
Have members of Congress traded Genmab A/s (GMAB)?
The most recent congressional trade disclosed in Genmab A/s is a purchase by Josh Gottheimer (house, NJ), dated 16 Jan 2025.
STOCK Act disclosures
| Traded | Member | Type | Amount | Filed after |
|---|---|---|---|---|
| 16 Jan 2025 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 25 days |
| 16 Dec 2024 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 29 days |
| 19 Jul 2024 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 27 days |
| 18 Jun 2024 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 21 days |
| 16 Oct 2023 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 26 days |
| 15 Sep 2023 | Josh Gottheimerhouse · Democrat–NJ | Sale | 1K USD–15K USD | 30 days |
| 20 Jul 2023 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 32 days |
| 19 Jul 2023 | Josh Gottheimerhouse · Democrat–NJ | Purchase | 1K USD–15K USD | 33 days |
What has been filed or recorded for Genmab A/s (GMAB)?
The filings we hold for Genmab A/s, newest first: 8 fails-to-deliver days and 5 reported financial figures, the latest dated 30 Oct 2026.
| And | ||||
|---|---|---|---|---|
| 30 Oct 2026 | Fails to deliver | Shares failed to deliver | 150,000 shares | 8.5M USD notional |
| 29 Oct 2026 | Fails to deliver | Shares failed to deliver | 42,502 shares | 2.4M USD notional |
| 28 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,940 shares | 87K USD notional |
| 27 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,194 shares | 53K USD notional |
| 26 Oct 2026 | Fails to deliver | Shares failed to deliver | 3,412 shares | 149K USD notional |
| 23 Oct 2026 | Fails to deliver | Shares failed to deliver | 588 shares | 24K USD notional |
| 15 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,082 shares | 40K USD notional |
| 08 Oct 2026 | Fails to deliver | Shares failed to deliver | 125 shares | 5K USD notional |
| 31 Dec 2025 | Financials | Revenue | 3.7B USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | 963.0M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted earnings loss per share | 15.37 USD | fiscal year |
| 31 Dec 2025 | Financials | Total assets | 12.9B USD | at period end |
| 31 Dec 2025 | Financials | Equity | 5.8B USD | at period end |
What is Reddit saying about Genmab A/s (GMAB)?
Reddit mentioned GMAB 1 times in the 30 days to 21 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 100% read bullish, 0% bearish and 0% neither. Reddit data updated 21 November 2026.
30-day window, Method
How do Reddit mentions of Genmab A/s (GMAB) compare with its price?
Share ↗
Before our first record — not zero
Which subreddits are talking about Genmab A/s (GMAB)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/stocks | 100% | 1 | +0.16 |
What do people ask about Genmab A/s (GMAB)?
What did Genmab A/s shares close at?50.62
Genmab A/s closed at 50.62 USD on 20 Nov 2026, down 1.38% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Genmab A/s’ revenue?3.7B
Genmab A/s reported revenue of 3.7B USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Which funds own Genmab A/s?8 of 45
8 of the 45 funds we track reported a Genmab A/s position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Two Sigma Investments, Point72 Asset Management and Renaissance Technologies. See Funds
Have members of Congress traded Genmab A/s?9 trades
Yes. 9 trades in Genmab A/s appear in the congressional disclosures we hold; the latest is a purchase by Josh Gottheimer (House, NJ) dated 16 Jan 2025, filed 10 Feb 2025. Amounts are disclosed as ranges, and a filing can follow the trade by up to 45 days. See Congress
What is Reddit saying about Genmab A/s?0 mentions
Genmab A/s was mentioned 0 times in the last 7 days across the finance subreddits we track, and 1 times over the trailing 30 days. Of the 1 mentions scored for sentiment, 100% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGAR13F filings
- Wikimedia CommonsPortraits via Wikimedia Commons. Josh Gottheimer: Kristie Boyd; U.S. House Office of Photography, Public domain.
- House disclosuresU.S. House of Representatives financial disclosures
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 31 Dec 2025
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words